Results 171 to 180 of about 174,911 (328)

A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy‐Induced Cardiotoxicity

open access: yesAdvanced Science, EarlyView.
In Yoo and Mainkar et al., we present a minimally invasive, CM‐selective modRNA delivery system encapsulated in lipid nanoparticles for intravenous (IV) administration. This platform enables selective cardiac translation of therapeutic modRNA but suppresses expression in off‐target tissues, including tumors.
Jimeen Yoo   +19 more
wiley   +1 more source

riboCIRC v2.0: an expanded resource for translatable CircRNAs. [PDF]

open access: yesNucleic Acids Res
Xu Y, Yang L, Tang Y, Wang Y, Wang H.
europepmc   +1 more source

Reviewer #2 (Public Review): Expanding the stdpopsim species catalog, and lessons learned for realistic genome simulations

open access: gold, 2023
Lauterbur M. Elise   +41 more
openalex   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

open access: yesAdvanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang   +13 more
wiley   +1 more source

Remembering Bob Ellett

open access: yes, 2013
Bordner, Georgianne
core   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy